Baseline characteristics (safety population)
| Cohort A | Cohort B | Cohort C | |||
| Efpeglenatide 6 mg QW (n=13) | Placebo (n=4) | Efpeglenatide 16 mg QM (n=13) | Placebo (n=4) | Liraglutide (n=13) | |
| Sex, n (%) | |||||
| Male | 9 (69.2) | 3 (75) | 6 (46.2) | 2 (50) | 7 (53.8) |
| Female | 4 (30.8) | 1 (25) | 7 (53.8) | 2 (50) | 6 (46.2) |
| Baseline characteristics, mean (SD) | |||||
| Age, years | 52.8 (6.09) | 51.3 (5.44) | 50.1 (11.68) | 56.8 (5.38) | 54.9 (9.58) |
| Weight, kg | 98.58 (15.714) | 87.98 (20.025) | 84.48 (17.567) | 77.45 (7.539) | 81.71 (17.413) |
| BMI, kg/m2 | 34.28 (4.269) | 30.33 (3.974) | 31.59 (5.981) | 28.93 (3.132) | 29.40 (5.132) |
| HbA1c (%) | 8.38 (1.125) | 9.28 (0.369) | 8.11 (1.135) | 7.93 (1.218) | 8.02 (0.727) |
BMI, body mass index; HbA1c, glycated hemoglobin; QM, once monthly; QW, once weekly; SD, standard deviation.